2025-12-29 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical Inc. (ISRG) based on the data provided.

**1. Return Rate Comparison:**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **ISRG Cumulative Return:** 113.53%
*   **VOO (S&P 500) Cumulative Return:** 103.21%
*   **Divergence:**
    *   Current: 10.7
    *   Relative Divergence: 35.5

**Analysis:** ISRG has outperformed the S&P 500 (VOO) over the given period, with a current cumulative return difference of approximately 10.7%. However, the relative divergence of 35.5 indicates that the current divergence is not at its historical peak, sitting at only 35.5% of the range. The outperformance suggests positive investor sentiment and company-specific growth drivers.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 77.6% | 40.0% | -0.1 | 43.6 |
| 2016-2018  | 64.0% | 72.2% | 49.0% | -0.0 | 57.2 |
| 2017-2019  | 54.0% | 72.2% | 31.0% | 0.2 | 70.6 |
| 2018-2020  | -6.0% | 80.4% | -29.0% | 0.3 | 97.8 |
| 2019-2021  | 29.0% | 80.4% | -18.0% | 0.6 | 128.8 |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2 | 95.1 |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7 | 120.9 |
| 2022-2024  | 36.0% | 77.5% | 15.0% | 1.7 | 187.1 |
| 2023-2025  | 76.0% | 72.7% | 8.0% | 0.8 | 207.1 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly, indicating periods of high growth (e.g., 2023-2025) and periods of negative growth (e.g., 2018-2020, 2020-2022, 2021-2023).
*   **MDD:** The Maximum Drawdown is consistently high, showing substantial potential for price drops.
*   **Alpha:** Alpha is generally positive in earlier periods but turns negative in recent years. This indicates that ISRG's performance, adjusted for risk, has underperformed its benchmark more recently.
*   **Beta:** Beta has increased over time, suggesting that ISRG's price movements have become more correlated with the market (S&P 500). A beta near or above 1 suggests the stock is as or more volatile than the market.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 577.81
*   **Previous Close:** 577.15
*   **Change:** 0.11
*   **5-day SMA:** 576.92
*   **20-day SMA:** 565.53
*   **60-day SMA:** 531.8071

**Analysis:** The stock is trading slightly above its 5-day SMA, significantly above its 20-day and 60-day SMAs. This indicates a short-term upward trend. The small change in price from the previous close suggests relative stability at the moment, but it is essential to monitor for larger price swings based on market events and news.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 51.47
*   **PPO:** 0.0937
*   **Hybrid Signal:** Buy 90% of cash (2 shares - Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** 8.0 (+) - Short-term increase
*   **Expected Return (%):** 23.9%

**Analysis:**

*   The MRI of 1.0 suggests a highly favorable market environment for investment based on this indicator.
*   The RSI of 51.47 indicates a neutral condition, not overbought or oversold.
*   The PPO (Percentage Price Oscillator) is positive but small, suggesting some upward momentum, but not extreme.
*   The Hybrid Signal recommends buying, albeit with caution, allocating only 90% of available cash.
*   The increase in relative divergence indicates a recent outperformance compared to the S&P 500.
*   The Expected Return of 23.9% is a significant potential upside if held long-term.

**4. Recent News & Significant Events:**

*   **World Investment Advisors Buys Shares:** MarketBeat reports World Investment Advisors increased their stake in ISRG.
*   **Stock Surged 30%:** Trefis attributes a recent surge to specific catalysts (details in the linked article).
*   **Valuation Revisited:** Yahoo Finance discusses revisiting valuation after a 25% price increase.
*   **FDA Greenlight & Buy Point:** Investor's Business Daily notes an FDA approval and a stock nearing a buy point.
*   **Intuitive Surgical (ISRG) Stock: What to Know Before the Market Opens on Dec. 26, 2025:** provides a news summary.
*   **ISRG vs. Stryker:** Zacks compares ISRG to Stryker, highlighting potential upside.

**Analysis:** The news flow is largely positive. Analysts are increasing their positions, the company received FDA approval, and the stock experienced a significant surge. However, articles discussing valuation after the surge suggest the market is assessing if the price is justified.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.06)
*   **Opinions:** 29
*   **Target Price:**
    *   Average: 599.60
    *   High: 700.00
    *   Low: 378.00
*   **Recent Rating Changes:** None specified in data.

**Analysis:** The strong buy consensus and generally positive target prices signal analyst confidence in ISRG. However, the wide range between the high and low target prices (378.00 to 700.00) indicates a considerable degree of uncertainty in the stock's future valuation.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-10-22 | 1.98 | 2.51 B$ |
| 2025-07-23 | 1.84 | 2.44 B$ |
| 2025-04-23 | 1.95 | 2.25 B$ |
| 2024-10-18 | 1.59 | 2.04 B$ |
| 2025-10-22 | 1.59 | 2.04 B$ |

**Analysis:** Revenue and EPS have been generally increasing over the past year, with a slight dip in EPS in 2025-07-23 before rebounding. The increasing revenue indicates strong demand for Intuitive Surgical's products and services. The EPS growth suggests improving profitability and efficiency.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $2.51B | 66.36% |
| 2025-06-30 | $2.44B | 66.31% |
| 2025-03-31 | $2.25B | 64.69% |
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $16.93B | 4.16% |
| 2025-06-30 | $17.85B | 3.69% |
| 2025-03-31 | $17.11B | 4.08% |
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |

**Analysis:**

*   **Revenue and Profitability:** Revenue has steadily increased over the last year, from $2.04B to $2.51B, indicating strong sales growth. The profit margin remains consistently high, ranging from 64.69% to 68.04%, showcasing the company's pricing power and operational efficiency.
*   **Capital and Profitability:** Equity has generally increased, reflecting the company's growing net worth. Return on Equity (ROE) has remained relatively stable, fluctuating between 3.63% and 4.17%, indicating consistent profitability relative to shareholders' equity.

**7. Comprehensive Analysis (Summary):**

Intuitive Surgical (ISRG) presents a mixed but generally positive picture.

*   **Strengths:**
    *   Outperformance of the S&P 500, although the relative divergence suggests it's not at its historical peak.
    *   Strong revenue and EPS growth.
    *   High and consistent profit margins.
    *   Positive analyst consensus and target prices.
    *   Favorable recent news, including FDA approval and institutional investment.
    *   High MRI score.
*   **Weaknesses/Risks:**
    *   High maximum drawdown indicating volatility.
    *   Recent negative alpha, suggesting recent underperformance relative to its benchmark.
    *   Increasing beta, indicating higher correlation with market volatility.
    *   Valuation concerns after recent price surge, as highlighted in news articles.
    *   Wide range of analyst target prices, indicating valuation uncertainty.

**Overall Conclusion:**

ISRG appears to be a fundamentally sound company with strong growth prospects, but it is not without risks. The recent price surge suggests that some of the near-term upside may already be priced in. While analysts are generally optimistic, the negative alpha and the wide range of target prices suggest caution. Investors should carefully consider their risk tolerance, investment horizon, and conduct further due diligence before making a decision. The high MRI suggests it's a good time to invest, but other factors, especially concerning recent volatility, should be taken into account.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.